Abstract High mammographic density is associated with a increased risk of breast cancer. We hypothesized that specific pathways exist that are associated with increased mammographic density, and may therefore be used to identify potential targets for chemoprevention. Histologically confirmed normal breast tissue was collected from women undergoing breast surgery who had available demographic data and mammograms for review. Women with low versus high mammographic breast density were compared. Differentially expressed genes using Affymetrix HG U133Plus2 chips were identified in dense versus nondense tissue. Immunohistochemical analysis (IHC) of estrogen receptor, progesterone receptor, Ki67, and COX2 expression was performed. About 66 women were identified, 28 (42%) had high, and 38 (58%) had low mammographic density. About 73 genes had differential expression between normal breast tissue with high and low mammographic density (P \ 0.001, fold change C1.5with a low false discovery rate (\10%). Network and canonical pathway analysis indicated decreased TGFb signaling (TGFBR2, SOS, SMAD3, CD44 and TNFRSF11B) in dense breast tissue relative to non-dense breast. By IHC, only COX2 expression in the stroma was statistically significant on multivariate analysis. TGFb ligands are currently the only growth factors known to prevent mammary epithelial cell proliferation. TGFb signaling has been reported to be inhibited by COX-2, and these molecules are highly differentially expressed in individuals at high risk of developing breast cancer. These results strongly suggest that COX2 inhibition should be investigated for breast cancer prevention despite possible increase in cardiovascular risk.
Introduction
Increased mammographic density is an independent, wellestablished, and robust risk factor for breast cancer. Women with dense breast tissue visible on mammography have an increased risk of breast cancer that is up to 6-fold higher compared to women with low mammographic breast density, matched for other variables, like age, menopausal status, weight, and parity [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . In addition, mammographic breast density has been shown to improve the discriminatory power of the Gail model for prediction of absolute invasive breast cancer risk [11] . Yet, the genetic and perhaps environmental factors responsible for increased breast density remain unknown. Possible explanations for the strong association of increased breast density and greater breast cancer risk may include elevated intra-mammary estrogen production with associated increased aromatase activity, increased signaling through pro-proliferative growth factor pathways such as Wnt, Notch, or Hedgehog, or the loss of negative control of epithelial proliferation. Identification and understanding of molecular pathways altered in dense versus non-dense breasts could lead to early therapeutic interventions to prevent the development of breast cancer in these high-risk individuals.
Enhanced estrogen receptor signaling is a known risk factor. Tamoxifen and raloxifene, selective estrogen receptor modulators, have been shown in several large multicenter studies to reduce the risk of developing breast cancer by 49% in women with a Gail risk greater than 1.7%. [5, [12] [13] [14] [15] . Likewise, aromatase inhibitors like letrozole, which lower plasma estradiol levels are being tested in clinical trials as chemopreventive agents [16] . These chemoprevention agents target the estrogen receptor (ER) pathway and are therefore only effective in preventing ERpositive breast cancers [5, [12] [13] [14] [15] [16] [17] [18] [19] . Pathways that may drive the development of ER-negative breast cancers are less well established, and there are no effective therapies in preventing the development of this potentially more aggressive tumor phenotype. Importantly, factors responsible for increased breast density and breast cancer risk may be lowered by appropriate chemoprevention agents.
We hypothesized that specific molecular pathways exist that are associated with increased mammographic density and breast cancer risk. The goals of this study were to (1) identify women with high and low mammographic density, (2) discover differential gene expression patterns of normal breast tissue in women with breast cancer with high and low breast density using the Affymetrix U133Plus 2 platform, and (3) confirm relevant target pathways by immunohistochemical (IHC) analysis of the normal breast in women with high and low breast densities.
Methods
We identified suitable patient samples from a frozen tissue bank consisting of more than a thousand specimens of normal breast obtained by excisional biopsy from mastectomy specimens in women undergoing surgery for breast cancer who did not have neoadjuvant chemotherapy or prior radiation and had preoperative mammograms available for review. The biopsy specimens were obtained at a distant site, at least 5 cm from the primary tumor. Over 250 mammograms were reviewed, and breast parenchymal density was classified by two different methods; firstly, according to the American College of Radiology's Breast Imaging-Reporting and Data System (BIRADS) [20] , and secondly, by quantitative assessment of percentage density of the mammographic parenchyma after digitizing mammograms using software from NIH Image and associated programs (http://rsb.info.nih.gov/nih-image/). The mammograms were independently reviewed by two radiologists specializing in mammography with two and twelve years experience in breast imaging respectively. Quantitative classification of mammographic parenchyma was based on radiological assessment after digitizing mammograms and measuring percentage density [1, 2, 8] . For differential gene expression patterns by group comparisons, we selected women who had low breast density (BIRADS 1 and 2) versus high density (BIRADS 3 and 4). In addition, we also analyzed density as a continuous variable for differentially expressed genes in both groups.
Normal breast tissue samples obtained from the study populations were embedded in OCT and longitudinally cut into 8 lM thick sections. A section of each specimen was examined by hematoxylin-eosin by a breast pathologist (AS), and only samples containing normal breast tissue with at least 60% epithelial content were selected. The methods for gene expression experiments have been described elsewhere [21] . Briefly, total RNA was isolated using TRIzol reagent (Invitrogen Corporation, Carlsbad, CA). Samples were then subsequently passed over a Qiagen RNeasy column (Qiagen, Valencia, CA). After RNA recovery, using a T7 promoter primer cDNA was synthesized, then fluorescently labeled and the labeled cRNA samples hybridized onto an Affymetrix U133Plus 2 Gene Chip which contains *34,000 genes, following the manufacturer's recommended procedures. Hybridized arrays were then scanned with a dual-laser based scanner. Pathway analysis of differentially expressed genes was performed using Ingenuity Pathway Analysis software. We also ran BioCarta pathway comparison using Functional class scoring method [22] with BRB Array Tools software (http://linus.nci.nih.gov/BRBArrayTools.html).
We then performed IHC analysis of relevant target signaling pathways, estrogen receptor (ER), progesterone receptor (PgR), proliferation index Ki67, and COX2, and scored the expression of these markers in the stroma and epithelium independently. The IHC analysis was performed on the corresponding mirror image of the specimen used for gene expression arrays. The IHC score for each biomarker was assessed by the pathologist (AS) who was blinded to the corresponding mammographic density of the specimens.
Statistical methods
For class comparison analyses (expression values versus density status, expression values versus menopausal status, and methylation values versus density status), we used t-tests on log values to rank the ''genes''. To adjust for multiple testing, we used a beta-uniform mixture (BUM) model to estimate the false discovery rate (FDR). High and low density subjects were compared with respect to IHC variables using the Wilcoxon rank sum test. All IHC factors were included in a single multiple variable logistic regression model with density status (high versus low) as the response variable. The model performance was quantified with respect to discrimination and calibration. Discrimination (i.e. whether the relative ranking of individual predictions is in the correct order) was quantified with the area under the receiver operating characteristic curve or with the concordance index, which is similar to the area under the receiver operating characteristic curve (AUC).
Results

Patient and sample characteristics
A total of 74 specimens from 66 women were obtained from women with known mammographic density. The median age of these women was 48 years (range 29, 88), and 27 women were premenopausal, while 39 women were postmenopausal. Of the women with high breast density, 19 (68%) were premenopausal, 9 (33%) were postmenopausal of whom 3 (11%) were on hormone replacement therapy (HRT) for more than one year. In women with low breast density, 8 women (21%) were premenopausal while 30 women (79%) were postmenopausal, of whom 9 (24%) were on HRT for more than 1 year (Table 1) .
Differential gene expression between high and low density normal breast tissue
The median RNA extracted was 25 lg (range 19-33 lg). The quality of the RNA was good, with high percent present calls between 40 and 50%, and with GADPH ratios of less than 1. BUM analysis was then conducted linking FDR values to specific P-value cut-offs which can then be compared to the observed P-values to compute the proportion of ''genes'' with lower P-values than the specified cut-off. The numbers of genes from the expression analysis on density (high/low density) that were significant with a FDR of 0.05 (5%) was 1,124, at 0.025: 423, at 0.010: 103, at 0.005: 29, and at 0.001: 4 genes.
Age and menopausal status were potential confounding variables, and by univariate analysis were associated with breast density. By logistic regression model with both age and menopausal status, breast density was only significantly associated with menopausal status ( Supplementary  Fig. 1 ). By further analysis, menopausal status alone yielded very few differentially expressed genes, there was only one gene from the expression analysis on menopausal status that was significant with an FDR of 5%.
We used an external cross-validation procedure (10-fold Monte Carlo Cross Validation, MCCV) on the top ranked 50-gene diagonal linear discriminant analysis (DLDA) model, with 2,500 iterations. The mean cross-validated Area Under the Receiver Operator Characteristic Curve (AUROCC) was 0.78, the standard deviation (SD) over the 2,500 iteration was 0.18, and the graph of the Area above the Curve (AAC = 1-AUC) is shown in Fig. 1 . Using a permutation test on the 50-gene DLDA model using the same cross-validation (10-fold MCCV), and 3,500 permutations, the maximum AUROCC was 0.76, giving a predictive accuracy with a P \ 0.0003. We also assessed how predictive accuracy changed with the number of top 5, 10, 20, 50, 75, 100, 150, 200, and 250 genes. The performance estimates were higher for the models with fewer genes, but this was not statistically significant with a standard deviation of 0.18.
We identified differentially expressed genes whose expression level differed by C1.5-fold at the P B 0.001 and P B 0.01 levels. At the P B 0.001 level, 26 uniquely named genes (30 probesets) were more highly expressed in dense versus non-dense breast (Table 2) , with 47 unique genes (57 probesets) showing lower expression in dense versus non-dense breast (Table 3) . At the P B 0.01 level, there were 84 probesets more highly expressed, and 150 probesets showing lower expression in dense versus nondense breasts.
Pathway analysis of genes differentially expressed in dense versus non-dense breast
For Ingenuity Pathway Analysis, we used the P B 0.001 dataset to afford a higher level of confidence in the analysis. Consistent with the difference in breast density due to increased connective tissue, the top six functions identified in the analysis (Fig. 2) were ''tissue morphology'' (12 molecules; P = 1.43E-06 -9.62E-03), ''connective tissue development and function'' (12 molecules; P = 7.12E-06 -1.44E-02), ''connective tissue disorders'' (8 molecules; P = 2.28E-05 -9.62E-03), ''developmental disorders'' (13 molecules; P = 2.28E-05 -9.62E-03), ''skeletal and muscular disorders'' (7 molecules; 2.28E-05 -1.07E-02) and ''tumor morphology'' (5 molecules; 2.28E-05 -1.16E-02). The 12 genes represented in ''tissue morphology'' were identical with those related to ''connective tissue development and function''. Most were involved in the regulation of adipose and connective tissue mass (DLK1, IGHG1, MARK2, PDPK1, SAT1, SMAD2, TNFSF11B) and/or in regulation of cell number (CD44, IL6ST, SMAD3, TNFRSF11B, ANGPT2).
The 13 genes were represented in ''developmental disorders'' (ANGPT2, ASPH, DCX, DLK1, IGHG1, IL6ST, NFIC, PDPK1, RELN S100A10, SMAD3, TGFBR2, TNFRSF11B) overlapped considerably with all genes in ''connective tissue disorder'' with the exception of MMP16 which was present only in the latter group. Likewise, there was considerable overlap with ''skeletal and muscular disorders'' given that many of these genes are involved in cartilage and bone development. These three disease-related categories thus also overlapped considerably with ''tissue morphology'' and ''connective tissue development and function''.
With respect to known gene networks, many of the genes listed above were represented in a cell-cell signaling network regulating tissue morphology. In particular, both network and canonical pathway analysis suggested decreased TGFb signaling in dense breast relative to non-dense breast. These differences included reduced expression of pathway components TGFBR2, SOS, and SMAD3, as well as reduced expression of two known TGFb target genes, CD44 and TNFRSF11B. Likewise, similar results were obtained using a functional class scoring method for BioCarta Pathway comparison, with reduced TGFb signaling in dense versus non-dense breasts (permutation P \ 0.005).
Confirmation of relevant signaling pathways by IHC analysis
We analyzed COX2 expression together with proliferation (Ki67) expression by IHC. The expression of steroid hormone receptors ER and PgR was also analyzed. The expression of each biomarker was scored according to the Allred scoring system by a breast pathologist (AS), who was blinded to the density status of the women. The epithelial and stromal marker expressions were scored independently.
By univariate analysis, COX2 expression in stroma and epithelium (P \ 0.001 and P \ 0.02, respectively), as well as Ki67 in the stroma, were significantly higher in dense versus non-dense breast (P \ 0.05). Steroid receptor (ER and PgR) expression was not significantly increased in dense versus non-dense breasts. By a multiple variable logistic regression model, only COX2 expression in the stroma was statistically significant at P \ 0.01.
Discussion
Mammographic density is associated with an established increased risk of breast cancer. Identification and analysis of molecular pathways responsible for this phenotype would be important for understanding the underlying causes of breast cancer, and could facilitate the design of effective therapeutic interventions targeted against these critical pathways that would ultimately prevent the development of the disease.
We have found that decreased TGFb signaling, and increased COX2 expression and proliferation in the stroma are highly differentially expressed in individuals at high risk of developing breast cancer.
TGFb ligands are currently the only growth factors known to prevent mammary epithelial cell proliferation. Reduced TGFb signaling, through reduced ligand or dominant negative TGFBR2 expression, was sufficient to promote tumor formation in mouse models [23] . TGFb has been shown to directly influence TNFRSF11B (osteoprotegerin) [24] , both of which showed decreased expression in dense compared to non-dense breast tissue. In addition, CD44, another known TGFb target [25, 26] , also showed reduced expression in dense versus non dense breast tissue. CD44 is regulated in conjunction with Wnt signaling, the second highest ranked canonical pathway identified by our gene expression analysis. We found elevated expression of MARK2 which regulates DVL, and SOX4-a TGFb1 target that interacts with TCF4 downstream of Wnt expression, although no ''canonical'' Wnt signaling components were identified in our analysis. Finally, and perhaps most importantly, consistent with this analysis, TGFb has been reported to be inhibited by COX-2 [27, 28] , and we found COX2 expression together with stromal Ki67 highly differentially expressed in normal breast tissue of dense breasts.
In a preclinical transgenic mouse MMTV-COX-2 model that overexpresses the COX-2 gene in the mammary glands, hyperplasia followed by frank transformation was observed in 100% of the mice within 7-14 months, supporting the role of COX2 as an oncogene [29] . MMTV-COX-2 induction of mammary hyperplasia is associated with increased prostaglandin E2 synthesis, increased aromatase activity, decreased BRCA1 levels, and induction of tumor-associated angiogenesis [30] [31] [32] . In humans, COX-2 expression has been observed in 41% of invasive breast cancers, and 80% of ductal carcinoma in situ (DCIS) [33] , and now, we report a higher expression in normal high-risk breast tissue with increased mammographic density. An earlier study by Schreinemacher and Everson suggested that non steroidal anti-inflammatory drugs (NSAIDS) may suppress the development of different cancers [34] . Later studies have focused on more specific inhibitors of the cyclooxygenase (COX) enzymes, COX-1 and COX-2. Of these, COX-2 inhibitors like celecoxib given for only 6 months have been shown to significantly reduce the number of colorectal polyps, a pre-cancerous condition, in individuals with familial polyposis [35, 36] . However, recently, in addition to the known rare side effects of gastrointestinal bleeding, increased cardiovascular events (thromboses, strokes, and myocardial infarction) were described in several large phase III studies (http://www. fda.gov/drug/infopage/COX2/default.htm). These studies demonstrating increased risk of cardiovascular events were primarily observed in individuals at risk of ischemic heart disease, who were administered COX-2 inhibitors at higher doses over several years. Based on these side effects and fears, recruitment to several COX-2 inhibitor chemopreventive studies in breast and other cancers have been curtailed [37, 38] .
There were some potential pitfalls with this study. First, mammographic density patterns may reflect differences in the amounts of varied cell types, including epithelial, stromal, or adipose cells in normal human breast tissue. The samples of normal breast tissue in this study were collected in OCT and snap frozen. Before RNA was extracted, a frozen section of the mirror image sample was evaluated histopathologically to characterize the ratio of epithelial, stromal, and adipose elements, and stroma. Because we elected not to perform laser-capture microdissection in order to better understand the contribution of global stromal interactions, the samples were selected with approximately equal admixture of stromal and epithelial components. Second, we dichotomized density into low and high density, according to the BIRADS criteria, while breast density is a continuous spectrum. We, however, found that the differentially expressed genes obtained by group comparison were highly statistically significant, with a low false discovery rate and accuracy, supporting the appropriate selection of specimens. We therefore analyzed breast density as a continuous variable, and found that the differentially expressed genes obtained by comparison were still statistically significant, with a low false discovery rate and accuracy, supporting the appropriate selection of samples. Third, these were normal samples in mastectomy specimens, and may not be truly representative of diseasefree women. Although histologically normal areas were sampled, there may theoretically be field effect changes that effected outcome.
In summary, we have demonstrated that decreased TGFb signaling, associated with increased stromal Ki67 expression and COX-2 expression is observed in mammographically dense breast, an established risk factor for breast cancer. These observations support the contention that COX2 inhibitors at different doses and schedules to minimize cardiovascular side effects should be further investigated for breast cancer prevention in high risk individuals.
